TD Cowen analyst Tyler Van Buren has maintained their bullish stance on NAMS stock, giving a Buy rating yesterday.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tyler Van Buren has given his Buy rating due to a combination of factors that highlight NewAmsterdam Pharma Company’s promising prospects. The company’s drug, obi, has shown significant cardiometabolic benefits, particularly in reducing major adverse cardiovascular events (MACE) by 21% in the BROADWAY trial. This impressive result, achieved within a year, is attributed to obi’s effects on lowering LDL-C and other lipids, which enhances its competitive positioning.
Furthermore, the acceptance of obi’s marketing authorization applications in the EU and its potential approval in 2026 add to the positive outlook. The recent data presentations at the American Heart Association (AHA) meeting further reinforced obi’s efficacy, particularly in comparison to other treatments like PCSK9 inhibitors. These factors collectively contribute to Van Buren’s confidence in the company’s future performance, leading to the Buy rating.
In another report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $60.00 price target.
Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NAMS in relation to earlier this year.